Chapter: 1 INTRODUCTION

1.1. REPORT DESCRIPTION
1.2. KEY BENEFITS
1.3. KEY MARKET SEGMENTS
1.4. RESEARCH METHODOLOGY

1.4.1. Secondary research
1.4.2. Primary research
1.4.3. Analyst tools & models

Chapter: 2 EXECUTIVE SUMMARY

2.1. CXO PERSPECTIVE

Chapter: 3 MARKET OVERVIEW

3.1. MARKET DEFINITION AND SCOPE
3.2. KEY FINDINGS

3.2.1. Top investment pockets
3.2.2. Top winning strategies

3.3. MARKET SHARE ANALYSIS, 2016
3.4. PORTER’S FIVE FORCES ANALYSIS
3.5. MARKET DYNAMICS

3.5.1. Drivers
3.5.2. Restraints
3.5.3. Opportunities

Chapter: 4 PULMONARY HYPERTENSION MARKET , BY PRODUCT

4.1. OVERVIEW

4.1.1. Market size and forecast

4.2. PROSTACYCLIN AND PROSTACYCLIN ANALOGS

4.2.1. Key market trends
4.2.2. Growth factors and opportunities
4.2.3. Market size and forecast

4.3. ENDOTHELIN RECEPTOR ANTAGONISTS

4.3.1. Key market trends
4.3.2. Growth factors and opportunities
4.3.3. Market size and forecast

4.4. PHOSPHODIESTERASE-5 INHIBITORS

4.4.1. Key market trends
4.4.2. Growth factors and opportunities
4.4.3. Market size and forecast

4.5. SOLUBLE GUANYLAYE CYCLASE STIMULATORS

4.5.1. Key market trends
4.5.2. Growth factors and opportunities
4.5.3. Market size and forecast

Chapter: 5 PULMONARY HYPERTENSION MARKET , BY APPLICATION

5.1. OVERVIEW

5.1.1. Market size and forecast

5.2. EARLY STAGE DRUG CANDIDATES (PHASE I & II)

5.2.1. Market size and forecast

5.3. LATE STAGE DRUG CANDIDATES (PHASE III & REGISTRAION PHASE)

5.3.1. Market size and forecast
5.3.2. Market size and forecast

Chapter: 6 PULMONARY HYPERTENSION MARKET , BY REGION

6.1. OVERVIEW
6.2. NORTH AMERICA

6.2.1. Key market trends
6.2.2. Key growth factors and opportunities
6.2.3. Market size and forecast

6.2.3.1. U.S. market size and forecast
6.2.3.2. Canada market size and forecast
6.2.3.3. Mexico market size and forecast

6.2.4. North America Pulmonary Hypertension Market by Product
6.2.5. North America Pulmonary Hypertension Market by Application

6.3. EUROPE

6.3.1. Key market trends
6.3.2. Key growth factors and opportunities
6.3.3. Market size and forecast

6.3.3.1. UK market size and forecast
6.3.3.2. Germany market size and forecast
6.3.3.3. France market size and forecast
6.3.3.4. Spain market size and forecast
6.3.3.5. Italy market size and forecast
6.3.3.6. Rest of Europe market size and forecast

6.3.4. Europe Pulmonary Hypertension Market by Product
6.3.5. Europe Pulmonary Hypertension Market by Application

6.4. ASIA-PACIFIC

6.4.1. Key market trends
6.4.2. Key growth factors and opportunities
6.4.3. Market size and forecast

6.4.3.1. China market size and forecast
6.4.3.2. Japan market size and forecast
6.4.3.3. India market size and forecast
6.4.3.4. Rest of Asia-Pacific market size and forecast

6.4.4. Asia-Pacific Pulmonary Hypertension Market by Product
6.4.5. Asia-Pacific Pulmonary Hypertension Market by Application

6.5. LAMEA

6.5.1. Key market trends
6.5.2. Key growth factors and opportunities
6.5.3. Market size and forecast

6.5.3.1. Latin America market size and forecast
6.5.3.2. The Middle East market size and forecast
6.5.3.3. Africa market size and forecast

6.5.4. LAMEA Pulmonary Hypertension Market by Product
6.5.5. LAMEA Pulmonary Hypertension Market by Application

Chapter: 7 COMPANY PROFILES

7.1. GLAXOSMITHKLINE PLC

7.1.1. Operating business segments
7.1.2. Business performance
7.1.3. Key strategic moves and developments

7.2. NOVARTIS AG

7.2.1. Operating business segments
7.2.2. Business performance
7.2.3. Key strategic moves and developments

7.3. MERCK & CO., INC.

7.3.1. Operating business segments
7.3.2. Business performance
7.3.3. Key strategic moves and developments

7.4. ABBOTT LABORATORIES

7.4.1. Operating business segments
7.4.2. Business performance
7.4.3. Key strategic moves and developments

7.5. BOEHRINGER INGELHEIM GMBH

7.5.1. Operating business segments
7.5.2. Business performance
7.5.3. Key strategic moves and developments

7.6. ASTRAZENECA PLC

7.6.1. Operating business segments
7.6.2. Business performance
7.6.3. Key strategic moves and developments

7.7. F. HOFFMANN-LA ROCHE AG

7.7.1. Operating business segments
7.7.2. Business performance
7.7.3. Key strategic moves and developments

7.8. TEVA PHARMACEUTICAL INDUSTRIES LTD

7.8.1. Operating business segments
7.8.2. Business performance
7.8.3. Key strategic moves and developments

7.9. VECTURA GROUP PLC

7.9.1. Operating business segments
7.9.2. Business performance
7.9.3. Key strategic moves and developments

7.10. PIFIZER INC.

7.10.1. Operating business segments
7.10.2. Business performance
7.10.3. Key strategic moves and developments